Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods.
暂无分享,去创建一个
[1] C. Porter,et al. The formulation of Halofantrine as either non-solubilizing PEG 6000 or solubilizing lipid based solid dispersions: physical stability and absolute bioavailability assessment. , 2000, International journal of pharmaceutics.
[2] M. Gibaldi,et al. New method of solid-state dispersion for increasing dissolution rates. , 1966, Journal of pharmaceutical sciences.
[3] D. Brooke,et al. Heat of fusion measurement of a low melting polymorph of carbamazepine that undergoes multiple-phase changes during differential scanning calorimetry analysis. , 1991, Journal of pharmaceutical sciences.
[4] Lynne S. Taylor,et al. Spectroscopic Characterization of Interactions Between PVP and Indomethacin in Amorphous Molecular Dispersions , 1997, Pharmaceutical Research.
[5] Emilio Squillante,et al. Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method. , 2002, Journal of pharmaceutical sciences.
[6] R. Löbenberg,et al. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[7] T. Nagai,et al. Studies on powdered preparation. XVII. Dissolution rate of sulfonamides by rotating disk method. , 1966, Chemical and pharmaceutical bulletin.
[8] L. Bertilsson. Clinical Pharmacokinetics of Carbamazepine , 1978, Clinical pharmacokinetics.
[9] S. Hoag,et al. Influence of various drugs on the glass transition temperature of poly(vinylpyrrolidone): a thermodynamic and spectroscopic investigation. , 2001, International journal of pharmaceutics.
[10] Ford Jl,et al. The current status of solid dispersions. , 1986 .
[11] F. Krahn,et al. Relations between several polymorphic forms and the dihydrate of carbamazepine. , 1987, Pharmaceutica acta Helvetiae.
[12] P. York,et al. Control of the Physical Form of Salmeterol Xinafoate , 1999 .
[13] York,et al. Strategies for particle design using supercritical fluid technologies. , 1999, Pharmaceutical science & technology today.
[14] B. Perissutti,et al. Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterisation, and in vitro dissolution. , 2001, International journal of pharmaceutics.
[15] George Zografi,et al. Physical Properties of Solid Molecular Dispersions of Indomethacin with Poly(vinylpyrrolidone) and Poly(vinylpyrrolidone-co-vinyl-acetate) in Relation to Indomethacin Crystallization , 1999, Pharmaceutical Research.
[16] J Dressman,et al. Improving drug solubility for oral delivery using solid dispersions. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[17] A. Serajuddin,et al. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. , 1999, Journal of pharmaceutical sciences.
[18] C. Rustichelli,et al. Solid-state study of polymorphic drugs: carbamazepine. , 2000, Journal of pharmaceutical and biomedical analysis.
[19] Patrick Augustijns,et al. Physico-chemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30 , 1998 .
[20] A. P. Lötter,et al. Physicochemical properties and X-ray structural studies of the trigonal polymorph of carbamazepine. , 1987, Journal of pharmaceutical sciences.
[21] R. Silverstein,et al. Spectrometric identification of organic compounds , 2013 .
[22] V. Krukonis,et al. Gas Antisolvent Recrystallization: New Process To Recrystallize Compounds Insoluble in Supercritical Fluids , 1989 .
[23] Stanley A. Kaplan,et al. Biopharmaceutical Considerations in Drug Formulation Design and Evaluation , 1972 .
[24] P Augustijns,et al. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[25] Emilio Squillante,et al. Solid dispersions: revival with greater possibilities and applications in oral drug delivery. , 2003, Critical reviews in therapeutic drug carrier systems.
[26] T. Higuchi,et al. Phase solubility techniques , 1965 .